MCID: BRN012
MIFTS: 60

Bronchiolitis Obliterans

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Bronchiolitis Obliterans

MalaCards integrated aliases for Bronchiolitis Obliterans:

Name: Bronchiolitis Obliterans 37 12 49 51 41 14 69
Obliterative Bronchiolitis 12 49 36
Bronchiolitis Fibrosa Obliterans 12 69
Bronchiolitis, Exudative 69
Bronchiolitis Exudativa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2799
MeSH 41 D001989
NCIt 46 C62580
SNOMED-CT 64 40100001
KEGG 36 H01873

Summaries for Bronchiolitis Obliterans

NIH Rare Diseases : 49 Bronchiolitis obliterans is an inflammatory condition that affects the lung's tiniest airways, the bronchioles. In affected people, the bronchioles may become damaged and inflamed leading to extensive scarring that blocks the airways. Signs and symptoms of the condition include a dry cough; shortness of breath; and/or fatigue and wheezing in the absence of a cold or asthma. Many different chemicals (such as nitrogen oxides, ammonia, welding fumes or food flavoring fumes) and respiratory infections can cause lung injury that leads to bronchiolitis obliterans. It can also be associated with rheumatoid arthritis and graft-versus-host disease following a lung or hematopoietic cell transplantation. While there is no way to reverse the disease, treatments are available that may stabilize or slow the progression. Another similarly named disease, bronchiolitis obliterans organizing pneumonia, is a completely different disease. Last updated: 11/1/2016

MalaCards based summary : Bronchiolitis Obliterans, also known as obliterative bronchiolitis, is related to cryptogenic organizing pneumonia and bronchiolitis. An important gene associated with Bronchiolitis Obliterans is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Miconazole and Montelukast have been mentioned in the context of this disorder. Affiliated tissues include Lung, lung and bone, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A obstructive lung disease involving obstruction of the bronchioles due to inflammation and fibrosis which occurs as a complication of various lung conditions or physiological insults.

Related Diseases for Bronchiolitis Obliterans

Diseases related to Bronchiolitis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)
# Related Disease Score Top Affiliating Genes
1 cryptogenic organizing pneumonia 33.9 CXCL8 MMP9 TIMP1
2 bronchiolitis 31.8 CXCL8 IFNG IL10 IL6 TNF
3 pneumonia 31.5 CXCL8 IL10 IL6 SCGB1A1 TNF
4 hematopoietic stem cell transplantation 31.1 IFNG IL10 IL6 TNF
5 acute respiratory distress syndrome 30.6 CXCL8 IL6 TNF
6 lung disease 30.5 CXCL8 IL10 MMP9 TNF
7 pulmonary disease, chronic obstructive 30.4 CXCL8 IL6 TNF
8 respiratory failure 30.4 CXCL8 IL10 SCGB1A1 TNF
9 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.4 IFNG IL10 IL17A
10 pulmonary edema 30.2 CXCL8 IL10 TNF
11 cystitis 30.1 CXCL8 IL6 TNF
12 ulcerative colitis 30.1 CXCL8 IFNG IL10 IL6 TNF
13 synovitis 30.1 CXCL8 IL6 TNF
14 rheumatic disease 30.1 IFNG IL10 TNF
15 myasthenia gravis 30.1 IFNG IL10 TNF
16 pulmonary tuberculosis 30.1 IFNG IL10 TNF
17 pulmonary sarcoidosis 30.0 CXCR3 IFNG TNF
18 colitis 29.9 CXCL8 IFNG IL10 IL17A IL6 TNF
19 adult respiratory distress syndrome 29.9 CXCL8 IL10 IL6 TNF
20 plasmodium vivax malaria 29.8 IFNG IL10 IL6 TNF
21 melioidosis 29.8 IFNG IL10 IL6 TNF
22 acquired immunodeficiency syndrome 29.8 IFNG IL10 IL6 TNF
23 chlamydia 29.8 CXCL8 IFNG IL10 IL6 TNF
24 graft-versus-host disease 29.8 GZMB IFNG IL10 IL6 TNF
25 mycobacterium tuberculosis 1 29.8 CXCR3 IFNG IL10 IL17A TNF
26 common variable immunodeficiency 29.8 IFNG IL10 IL6 TNF
27 arthritis 29.7 CXCL8 IFNG IL10 IL17A IL6 MMP9
28 systemic lupus erythematosus 29.6 CXCR3 IFNG IL10 IL17A IL6 TNF
29 cytomegalovirus infection 29.6 CXCL8 IFNG IL10 IL6 TNF
30 wegener granulomatosis 29.6 CXCL8 IFNG IL10 IL6 TNF
31 rheumatoid arthritis 29.5 CXCL8 IFNG IL10 IL17A IL6 TIMP1
32 acute graft versus host disease 29.3 GZMB IFNG IL10 TNF
33 inflammatory bowel disease 29.2 CXCL8 IFNG IL10 IL17A IL6 TNF
34 asthma 28.9 CXCL8 IFNG IL10 IL17A IL6 MMP9
35 bone inflammation disease 28.8 CXCL8 IFNG IL10 IL17A IL6 TIMP1
36 malaria 28.4 CXCL8 CXCR3 IFNG IL10 IL17A IL6
37 pulmonary fibrosis, idiopathic 28.3 CXCL8 CXCR3 IFNG MMP9 PDGFB SCGB1A1
38 bronchiolitis obliterans with obstructive pulmonary disease 12.4
39 punctate inner choroidopathy 10.5 IL10 TNF
40 tropical endomyocardial fibrosis 10.5 IL10 TNF
41 staphylococcal toxic shock syndrome 10.5 IFNG TNF
42 vibratory urticaria 10.5 CXCL8 MMP9
43 autoimmune myocarditis 10.5 IFNG TNF
44 scorpion envenomation 10.5 IL6 TNF
45 amaurosis fugax 10.5 MMP8 MMP9
46 pemphigus 10.5
47 paraneoplastic pemphigus 10.5
48 acute generalized exanthematous pustulosis 10.5 CXCL8 IL17A
49 recurrent corneal erosion 10.5 CXCL8 IL6
50 hyperlucent lung 10.5 IFNG IL10

Graphical network of the top 20 diseases related to Bronchiolitis Obliterans:



Diseases related to Bronchiolitis Obliterans

Symptoms & Phenotypes for Bronchiolitis Obliterans

MGI Mouse Phenotypes related to Bronchiolitis Obliterans:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.11 TNF TIMP1 IL6 CXCR3 MMP8 MMP9
2 hematopoietic system MP:0005397 10.06 TNF TIMP1 IL6 CXCR3 MMP9 IFNG
3 immune system MP:0005387 10.06 TNF TIMP1 IL6 CXCR3 MMP8 MMP9
4 neoplasm MP:0002006 9.81 TNF TIMP1 IL6 CXCR3 MMP8 MMP9
5 integument MP:0010771 9.8 TNF IL6 EVPL MMP9 IFNG PDGFB
6 renal/urinary system MP:0005367 9.5 IL6 CXCR3 MMP9 IFNG PDGFB IL17A
7 respiratory system MP:0005388 9.32 TNF CXCR3 MMP9 IFNG PDGFB IL10

Drugs & Therapeutics for Bronchiolitis Obliterans

Drugs for Bronchiolitis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
2
Montelukast Approved Phase 4,Phase 2 158966-92-8 5281040
3
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 53477736 447043 55185
4
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
5
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
6
Mechlorethamine Approved, Investigational Phase 4,Phase 3 51-75-2 4033
7
Azathioprine Approved Phase 4 446-86-6 2265
8
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
9
Prednisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 53-03-2 5865
10
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
11
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 104987-11-3 445643 439492
12
Macitentan Approved Phase 4 441798-33-0
13
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Bone Density Conservation Agents Phase 4
21 Ergocalciferols Phase 4
22 Micronutrients Phase 4
23 Trace Elements Phase 4
24 Vitamins Phase 4
25 Anti-Asthmatic Agents Phase 4,Phase 2
26 Cysteinyl-leukotriene Phase 4
27 Hormone Antagonists Phase 4,Phase 2,Phase 1
28 Hormones Phase 4,Phase 2,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
30 Leukotriene Antagonists Phase 4,Phase 2
31 Respiratory System Agents Phase 4,Phase 2
32 Adrenergic Agents Phase 4,Phase 2
33 Adrenergic Agonists Phase 4,Phase 2
34 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
35 Adrenergic beta-Agonists Phase 4,Phase 2
36 Albuterol Phase 4
37 Autonomic Agents Phase 4,Phase 2
38 Bromides Phase 4
39 Bronchodilator Agents Phase 4,Phase 2
40 Cholinergic Agents Phase 4
41 Cholinergic Antagonists Phase 4
42 Neurotransmitter Agents Phase 4,Phase 2
43 Parasympatholytics Phase 4
44 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Tiotropium Bromide Phase 4 136310-93-5
46 Tocolytic Agents Phase 4
47 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
48 Erythromycin Estolate Phase 4
49 Erythromycin Ethylsuccinate Phase 4
50 Erythromycin stearate Phase 4

Interventional clinical trials:

(show top 50) (show all 95)

# Name Status NCT ID Phase Drugs
1 Vitamin D in Bronchiolitis Obliterans Syndrome Completed NCT01212406 Phase 4 Vitamin D
2 Montelukast in Bronchiolitis Obliterans Syndrome Completed NCT01211509 Phase 4 Montelukast
3 Bronchodilator Responsiveness in Obliterative Bronchiolitis Completed NCT01112241 Phase 4 albuterol plus tiotropium
4 Azithromycin in Bronchiolitis Obliterans Syndrome Completed NCT01009619 Phase 4 Azithromycin;Placebo
5 Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) Completed NCT01469364 Phase 4 Aztreonam Lysine for Inhalation (AZLI)
6 Use of Erythromycin in Mustard-Induced Bronchiolitis Completed NCT00367419 Phase 4 Erythromycin
7 Comparison of Sirolimus and Azathioprine in Lung Transplantation Completed NCT00321906 Phase 4 azathioprine;sirolimus
8 Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation Completed NCT01109160 Phase 4 Azithromycin Dihydrate
9 Macitentan in the Treatment of Organ Rejection After Lung Transplantation Not yet recruiting NCT02893176 Phase 4 macitentan;placebo (for macitentan)
10 Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation Completed NCT01429844 Phase 3 Tacrolimus;Cyclosporine
11 Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation Completed NCT00755781 Phase 3 Cyclosporine Inhalation Solution (CIS)
12 Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant Completed NCT00188825 Phase 3 basiliximab
13 Use of Clarithromycin in Mustard-Induced Bronchiolitis Completed NCT00381147 Phase 3 Clarithromycin
14 Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation Completed NCT00402532 Phase 3 Everolimus;Mycophenolatmofetil
15 Efficacy of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients Completed NCT01404325 Phase 3 standard therapy;Everolimus (RAD001) as add-on;RAD001
16 European Trial of Pirfenidone in BOS, A European Multi-center Study Recruiting NCT02262299 Phase 2, Phase 3 Pirfenidone;Placebo
17 Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children Recruiting NCT02426112 Phase 3 Azithromycin;Placebo
18 Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting NCT01959100 Phase 3 Azithromycin;Placebo
19 Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 1-2 Not yet recruiting NCT03283007 Phase 3 Nintedanib;Placebo
20 Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) Terminated NCT01439958 Phase 3 Inhalation
21 L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients Terminated NCT01334892 Phase 2, Phase 3 Cyclosporine Inhalation Solution
22 CIS001 Extension Study of Cyclosporine Inhalation Solution Terminated NCT00938236 Phase 3 Cyclosporine Inhalation Solution (CIS)
23 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
24 A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT Unknown status NCT01639261 Phase 2 Interferon gamma 1b
25 Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Unknown status NCT00472225 Phase 2 Rituximab
26 Targeted Therapy of Bronchiolitis Obliterans Syndrome Completed NCT01307462 Phase 2 fluticasone propionate;montelukast sodium;azithromycin
27 Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation Completed NCT01560689 Phase 2 Budesonide/formoterol;Placebo
28 Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients Completed NCT01650545 Phase 1, Phase 2 Liposomal aerosol cyclosporine
29 Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT Completed NCT00624754 Phase 2 Formoterol/Budesonide;lactose
30 Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant Completed NCT00141726 Phase 2 Etanercept
31 Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation Completed NCT00029328 Phase 1, Phase 2 etanercept
32 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Recruiting NCT01273207 Phase 2 Inhaled Cyclosporine Solution
33 AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT02669251 Phase 1, Phase 2 AZD9668
34 Prospective Study for Transplant Optimization Using Functional Imaging (TROFI) Recruiting NCT02488304 Phase 2
35 MSC for Treatment of Interstitial Lung Disease After Allo-HSCT Recruiting NCT02543073 Phase 1, Phase 2 AZM;Glucocorticoid
36 Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease Recruiting NCT02960503 Phase 1, Phase 2 Azithromycin
37 Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction Recruiting NCT02709343 Phase 2 Bone-marrow derived MSCs;Placebo
38 Montelukast to Treat Bronchiolitis Obliterans Active, not recruiting NCT00656058 Phase 2 Singulair (Montelukast Sodium)
39 Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Active, not recruiting NCT01287078 Phase 2 Cyclosporine Inhalation Solution
40 A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD Active, not recruiting NCT01163786 Phase 2 Bortezomib
41 Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation Active, not recruiting NCT02614872 Phase 2 GLASSIA® and Institution standard of care (SOC)
42 Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Active, not recruiting NCT02036970 Phase 2 Bardoxolone methyl;Placebo
43 The Safety and Tolerability of Pirfenidone for BOS After HCT Not yet recruiting NCT03315741 Phase 2 Pirfenidone 267 MG [Esbriet]
44 Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant Terminated NCT01432080 Phase 2 Prednisone;Azithromycin;Montelukast;Symbicort
45 A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation Completed NCT01175655 Phase 1
46 Mesenchymal Stem Cell Therapy for Lung Rejection Completed NCT02181712 Phase 1
47 Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation Unknown status NCT00774449
48 Dry Powder Inhalation of Cyclosporine A in Lung Transplant Patients With Bronchiolitis Obliterans Syndrome Unknown status NCT00378677 Early Phase 1 Cyclosporine A dry powder inhalation (Drug)
49 Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO Unknown status NCT02627833
50 Immune Mechanisms of Rejection in Human Lung Allografts Unknown status NCT00861900

Search NIH Clinical Center for Bronchiolitis Obliterans

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchiolitis Obliterans cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchiolitis Obliterans:
Mesenchymal stem cells for obliterative bronchiolitis
Embryonic/Adult Cultured Cells Related to Bronchiolitis Obliterans:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: bronchiolitis obliterans

Genetic Tests for Bronchiolitis Obliterans

Anatomical Context for Bronchiolitis Obliterans

MalaCards organs/tissues related to Bronchiolitis Obliterans:

38
Lung, Bone, Bone Marrow, Breast, T Cells, Heart, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchiolitis Obliterans:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Respiratory Bronchioles Cilliated Cells Potential therapeutic candidate, affected by disease

Publications for Bronchiolitis Obliterans

Articles related to Bronchiolitis Obliterans:

(show top 50) (show all 846)
# Title Authors Year
1
Bronchiolitis obliterans organizing pneumonia after stereotactic ablative radiation therapy for lung cancer: A case report. ( 29395853 )
2018
2
Bronchiolitis Obliterans and Pulmonary Fibrosis After Sulfur Mustard Inhalation in Rats. ( 29314868 )
2018
3
Tocilizumab Cannot Prevent the Development of Bronchiolitis Obliterans in Patients With Castleman Disease-Associated Paraneoplastic Pemphigus. ( 29389687 )
2018
4
Efficacy of high-dose steroids for bronchiolitis obliterans syndrome post pediatric hematopoietic stem cell transplantation. ( 29417689 )
2018
5
Bronchiolitis obliterans syndrome is associated with increased p-glycoprotein expression and loss of glucocorticoid receptor from steroid-resistant proinflammatory CD8<sup>+</sup>T cells. ( 29352737 )
2018
6
Mycobacterium abscessus and massiliense lung infection during macrolide treatment for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. ( 28988958 )
2018
7
Post-infectious bronchiolitis obliterans in children: is general quality of life the right measure? ( 29438684 )
2018
8
Evaluating for Bronchiolitis Obliterans with Low Attenuation CT 3D Reconstructions. ( 29406777 )
2018
9
Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review. ( 28662986 )
2017
10
Effects of Intraperitoneal Injection of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells on Bronchiolitis Obliterans in Mice Model. ( 28732434 )
2017
11
Lung Clearance Index and Quantitative Computed Tomography of Post-Infectious Bronchiolitis Obliterans in Infants. ( 29123150 )
2017
12
Mycoplasma pneumoniae-Associated Bronchiolitis Obliterans Following Acute Bronchiolitis. ( 28814783 )
2017
13
Bronchiolitis Obliterans (Obliterative Bronchiolitis, Constrictive Bronchiolitis) ( 28722895 )
2017
14
Development of a Multivariate Prediction Model for Early-Onset Bronchiolitis Obliterans Syndrome and Restrictive Allograft Syndrome in Lung Transplantation. ( 28770204 )
2017
15
Respiratory reactance in children aged three to fiveA years with postinfectious bronchiolitis obliterans is higher than in those with asthma. ( 27743492 )
2017
16
Inert Gas Washout in Bronchiolitis Obliterans Following Hematopoietic Cell Transplantation. ( 29275133 )
2017
17
Health-related quality of life in patients with bronchiolitis obliterans. ( 29172039 )
2017
18
Double lung, unlike single lung transplantation might provide a protective effect on mortality and bronchiolitis obliterans syndrome. ( 29178919 )
2017
19
Serum YKL-40 levels may help distinguish exacerbation of post-infectious bronchiolitis obliterans from acute bronchiolitis in young children. ( 28567534 )
2017
20
Impact of Forced Expiratory Volume in 1 Second (FEV1) and 6-Minute Walking Distance at 3, 6, and 12 Months and Annually on Survival and Occurrence of Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation. ( 28871078 )
2017
21
Development of bronchiolitis obliterans organizing pneumonia during standard treatment of hepatitis C with Peg-IFNI+2b. ( 28823117 )
2017
22
Early extracellular matrix changes are associated with later development of bronchiolitis obliterans syndrome after lung transplantation. ( 28469930 )
2017
23
Diacetyl and occupational bronchiolitis obliterans: Comments on Rose, CS: Early detection, clinical diagnosis and management of lung disease from exposure to diacetyl, toxicology (2017), https://doi.org/10.1016/j.tox.2017.03.019. ( 29054810 )
2017
24
Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome. ( 29375549 )
2017
25
Chest computed tomography in bronchiolitis obliterans after bone marrow transplantation. ( 28670041 )
2017
26
LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats. ( 28545478 )
2017
27
Serum miRNAs as potential biomarkers for the bronchiolitis obliterans syndrome after lung transplantation. ( 28457921 )
2017
28
An autopsy case of bronchiolitis obliterans as a previously unrecognized adverse event of afatinib treatment. ( 28012496 )
2017
29
A case of bronchiolitis obliterans organising pneumonia associated with SAPHO (synovitis-acne-pustulosis-hyperostosis-osteitis) syndrome. ( 28765183 )
2017
30
Cathelicidin (LL-37) and human I^2-defensin levels of children with post-infectious bronchiolitis obliterans. ( 26073571 )
2017
31
Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease. ( 28894914 )
2017
32
Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation. ( 28752350 )
2017
33
Efficacy of Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome After Lung Transplantation. ( 28457374 )
2017
34
The role of epithelial-mesenchymal transition in the post-lung transplantation bronchiolitis obliterans. ( 29262833 )
2017
35
Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. ( 29128013 )
2017
36
Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. ( 28052713 )
2017
37
Clinical Analysis of Unicentric Castleman's Disease with Paraneoplastic Pemphigus and Bronchiolitis Obliterans. ( 28877826 )
2017
38
Achievement of the longest survival of paraneoplastic pemphigus with bronchiolitis obliterans associated with follicular lymphoma using R-CHOP chemotherapy. ( 28791608 )
2017
39
Multivariate modeling using quantitative CT metrics may improve accuracy of diagnosis of bronchiolitis obliterans syndrome after lung transplantation. ( 28850899 )
2017
40
Repeated systemic administration of adipose tissue-derived mesenchymal stem cells prevents tracheal obliteration in a murine model of bronchiolitis obliterans. ( 28528427 )
2017
41
Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. ( 27513368 )
2016
42
Observational Study of Methotrexate in the Treatment of Bronchiolitis Obliterans Syndrome. ( 27931586 )
2016
43
Identification of miRNAs Potentially Involved in Bronchiolitis Obliterans Syndrome: A Computational Study. ( 27564214 )
2016
44
MicroRNA-144 is unlikely to play a role in bronchiolitis obliterans syndrome. ( 26874429 )
2016
45
Non-paraneoplastic autoimmune subepidermal bullous disease associated with fatal bronchiolitis obliterans. ( 27914107 )
2016
46
Proteomic characterization reveals that MMP-3 correlates with bronchiolitis obliterans syndrome following allogeneic hematopoietic cell and lung transplantation. ( 26887344 )
2016
47
HMGB1 exacerbates bronchiolitis obliterans syndrome via RAGE/NF-I_B/HPSE signaling to enhance latent TGF-I^ release from ECM. ( 27347307 )
2016
48
Risk Factor and Clinical Outcome of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. ( 26847288 )
2016
49
Phenytoin induced Steven-Johnson syndrome and bronchiolitis obliterans - case report and review of literature. ( 27222786 )
2016
50
Evaluating bronchodilator response in pediatric patients with post-infectious bronchiolitis obliterans: use of different criteria for identifying airway reversibility. ( 27383929 )
2016

Variations for Bronchiolitis Obliterans

Expression for Bronchiolitis Obliterans

Search GEO for disease gene expression data for Bronchiolitis Obliterans.

Pathways for Bronchiolitis Obliterans

Pathways related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 CXCL8 IFNG IL10 IL17A IL6 MMP8
2
Show member pathways
13.81 CXCL8 CXCR3 IL10 IL17A IL6 PDGFB
3
Show member pathways
13.64 CXCL8 CXCR3 IFNG IL10 IL17A IL6
4
Show member pathways
13.54 CXCL8 IFNG IL10 IL17A IL6 PDGFB
5
Show member pathways
13.39 CXCL8 CXCR3 IL10 IL17A IL6 PDGFB
6
Show member pathways
13.35 CXCL8 IFNG IL10 IL17A IL6 MMP9
7
Show member pathways
13.28 CXCL8 CXCR3 IL10 IL17A IL6 PDGFB
8
Show member pathways
12.86 CXCL8 GZMB IFNG IL10 IL17A IL6
9 12.84 CXCL8 IFNG IL6 MMP9 PDGFB
10
Show member pathways
12.61 IFNG IL10 IL17A IL6 TNF
11
Show member pathways
12.59 CXCL8 IL6 MMP9 PDGFB TNF
12 12.57 GZMB IFNG IL10 IL17A TNF
13
Show member pathways
12.55 CXCL8 IFNG IL10 IL6 TNF
14
Show member pathways
12.51 IFNG IL10 IL17A IL6 PDGFB TIMP1
15
Show member pathways
12.45 IFNG IL10 IL17A IL6 TNF
16
Show member pathways
12.39 IFNG IL10 IL6 PDGFB
17
Show member pathways
12.29 CXCL8 IFNG IL6 TNF
18
Show member pathways
12.29 CXCL8 IFNG IL17A IL6 MMP9 TNF
19 12.28 CXCL8 GZMB IL6 MMP9
20 12.26 IFNG IL10 IL6 TNF
21
Show member pathways
12.21 CXCL8 IFNG IL6 TNF
22 12.21 IFNG IL6 MMP9 TNF
23 12.2 CXCL8 IL10 IL6 TNF
24 12.12 IFNG MMP9 PDGFB TNF
25
Show member pathways
12.05 CXCL8 IFNG IL10 IL17A IL6 TNF
26 12.04 CXCL8 IFNG IL6 MMP9 TNF
27 12.02 IFNG IL10 IL6 TNF
28 11.95 IL6 MMP9 TNF
29
Show member pathways
11.95 IFNG IL10 IL17A IL6 TNF
30 11.94 CXCL8 IFNG IL6
31
Show member pathways
11.93 MMP8 MMP9 TIMP1 TNF
32 11.91 IFNG IL6 TIMP1
33 11.9 CXCL8 IL6 TNF
34
Show member pathways
11.89 GZMB IFNG IL17A IL6
35
Show member pathways
11.88 CXCL8 IL17A IL6
36 11.87 CXCL8 IFNG IL10 IL6 TNF
37 11.84 CXCL8 IFNG IL6
38 11.82 CXCL8 IFNG IL6
39 11.81 CXCL8 IFNG IL17A IL6 TNF
40 11.79 CXCL8 IL10 IL6 TNF
41
Show member pathways
11.78 CXCL8 IFNG TNF
42 11.78 IFNG IL10 IL6 TNF
43 11.72 IL10 IL6 TNF
44 11.71 CXCL8 IL6 MMP9
45 11.68 CXCL8 MMP9 TIMP1
46
Show member pathways
11.68 GZMB IFNG TNF
47 11.63 CXCL8 IFNG IL6
48 11.63 CXCL8 IL6 TNF
49
Show member pathways
11.6 CXCL8 IFNG IL6 MMP9 TNF
50 11.59 IFNG IL6 TNF

GO Terms for Bronchiolitis Obliterans

Cellular components related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CXCL8 IFNG IL10 IL17A IL6 MMP8
2 extracellular matrix GO:0031012 9.46 MMP8 MMP9 PDGFB TIMP1
3 extracellular space GO:0005615 9.36 CXCL8 IFNG IL10 IL17A IL6 MMP8

Biological processes related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.88 CXCL8 IFNG IL10 IL17A IL6 TNF
2 positive regulation of DNA binding transcription factor activity GO:0051091 9.79 IL10 IL6 TNF
3 movement of cell or subcellular component GO:0006928 9.77 CXCL8 CXCR3 IFNG
4 extracellular matrix disassembly GO:0022617 9.76 MMP8 MMP9 TIMP1
5 cellular response to lipopolysaccharide GO:0071222 9.76 CXCL8 IL10 IL6 TNF
6 inflammatory response GO:0006954 9.73 CXCL8 CXCR3 IL10 IL17A IL6 TNF
7 positive regulation of smooth muscle cell proliferation GO:0048661 9.72 IL6 PDGFB TNF
8 humoral immune response GO:0006959 9.71 IFNG IL6 TNF
9 embryonic digestive tract development GO:0048566 9.63 CXCL8 TNF
10 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 IFNG TNF
11 response to organic substance GO:0010033 9.62 IL10 SCGB1A1 TIMP1 TNF
12 negative regulation of growth of symbiont in host GO:0044130 9.61 IL10 TNF
13 response to molecule of bacterial origin GO:0002237 9.61 CXCL8 IL10
14 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.6 IL10 TNF
15 negative regulation of lipid storage GO:0010888 9.58 IL6 TNF
16 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.57 IL10 TIMP1
17 endothelial cell apoptotic process GO:0072577 9.56 IL10 TNF
18 positive regulation of osteoclast differentiation GO:0045672 9.54 IFNG IL17A TNF
19 negative regulation of cytokine secretion involved in immune response GO:0002740 9.52 IL10 TNF
20 positive regulation of interleukin-23 production GO:0032747 9.51 IFNG IL17A
21 receptor biosynthetic process GO:0032800 9.49 IL10 TNF
22 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 IFNG TNF
23 response to glucocorticoid GO:0051384 9.46 IL10 IL6 SCGB1A1 TNF
24 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 IFNG TNF
25 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.26 IL10 MMP9 PDGFB TNF
26 regulation of receptor activity GO:0010469 9.23 CXCL8 IFNG IL10 IL17A IL6 PDGFB

Molecular functions related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL10 IL6 PDGFB TIMP1
2 cytokine activity GO:0005125 9.17 CXCL8 IFNG IL10 IL17A IL6 TIMP1

Sources for Bronchiolitis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....